Since December 2020, the Minnesota Department of Health (MDH) Public Health Laboratory has been receiving 100 specimens per week (50 from each of two clinical partners) with low cycle threshold (Ct) values for routine surveillance for SARS-CoV-2, the virus that causes COVID-19. On January 25, 2021, MDH identified the SARS-CoV-2 variant P.1 in one specimen through this surveillance system using whole genome sequencing, representing the first identified case of this variant in the United States. The P.1 variant was first identified in travelers from Brazil during routine airport screening in Tokyo, Japan, in early January 2021 (1). This variant has been associated with increased transmissibility (2), and there are concerns that mutations in the spike protein receptor-binding domain might disrupt both vaccine-induced and natural immunity (3,4). As of February 28, 2021, a total of 10 P.1 cases had been identified in the United States, including the two cases described in this report, followed by one case each in Alaska, Florida, Maryland, and Oklahoma (5).

中文翻译：

---

美国于2021年1月在明尼苏达州首次发现SARS-CoV-2变体P.1的病例。

自2020年12月以来，明尼苏达州卫生部（MDH）的公共卫生实验室每周接受100份标本（两个临床合作伙伴各50份），其循环阈值（Ct）值较低，以进行SARS-CoV-2的常规监测。导致COVID-19的病毒。2021年1月25日，MDH通过使用全基因组测序的监测系统在一个标本中鉴定出SARS-CoV-2变体P.1，代表了该变体在美国的首例确诊病例。P.1变体是2021年1月上旬在日本东京进行例行机场检查时首先在巴西的旅行者中发现的（1）。该变体与增加的可传播性相关（2），并且人们担心棘突蛋白受体结合结构域的突变可能会破坏疫苗诱导的免疫力和自然免疫力（3,4）。